Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inhaled virus takes on lung tumors in new trial

NCT ID NCT06228326

Disease control Sponsor: Krystal Biotech, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an inhaled treatment called KB707, a modified herpes virus designed to trigger the immune system against lung tumors. It is for adults with advanced solid tumors that have spread to the lungs and who have run out of standard options. The trial will test KB707 alone and in combination with Keytruda or chemotherapy to see if it is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
genetically modified herpes simplex virus (KB707)
What this could lead to
If successful, this could offer a new inhaled treatment option for people with advanced lung cancers that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. The virus-based therapy may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Age 18 years or older at the time of informed consent * Life expectancy \>12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Have at least one measurable lung lesion per RECIST v1.1 at Screening * Cohorts 1 through 4 only: Histologically confirmed diagnosis of advanced solid tumor malignancy affecting the lungs and the individual has progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or has no standard of care therapy. * Cohorts 5, 6, and 7 only: (1) Histologically or cytologically confirmed diagnosis of stage 3 or 4 NSCLC, as per American Joint Committee on Cancer (AJCC) staging system (8th edition) and (2) Subject must meet the following criteria of prior lines of therapy: 1. Subject has previously received no more than one line of prior immune checkpoint inhibitor (ICI) with or without platinum-based chemotherapy, or no more than two prior lines of therapy when given the ICI and platinum-based chemotherapy sequentially as two separate lines. 2. Subjects with an actionable mutation (e.g., EGFR, KRAS, ALK, or ROS1 genomic alteration), are permitted to have received one additional line of approved targeted therapy. Key Exclusion Criteria: * Not fully recovered from prior surgery or radiotherapy, including all radiation-related toxicities * The subject is pregnant, nursing, or plans to become pregnant during study treatment and through three months after the last dose of KB707 * Have known history of positive human immunodeficiency virus (HIV 1/2) * Cohorts 5, 6, and 7 only: 1. Subject has a known additional malignancy that is progressing or requires active treatment 2. Subject has active brain metastases or leptomeningeal metastases 3. Prior anti-PD-1/PD-L1 therapy was intolerable and required discontinuation of treatment 4. Subject has active, known, or suspected autoimmune disease requiring systemic treatment 5. Subject has known acute or chronic hepatitis 6. Subject has active pneumonitis or history of ICI-induced pneumonitis that required steroids

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer lung cancer lung neoplasm metastatic malignant neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced cancer Lung cancer (non-small cell) Lung cancer (NSCLC) Lung cancer metastatic Solid tumor, adult

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • BRCR Global

    RECRUITING

    Weston, Florida, 33326, United States

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Emad Ibrahim MD Inc

    RECRUITING

    Redlands, California, 92373, United States

  • Gabrail Cancer Center Research

    RECRUITING

    Canton, Ohio, 44718, United States

  • Henry Ford Health

    RECRUITING

    Detroit, Michigan, 48202, United States

  • HonorHealth Research Institute

    RECRUITING

    Scottsdale, Arizona, 85258, United States

  • IU Simon Comprehensive Cancer Center

    TERMINATED

    Indianapolis, Indiana, 46202, United States

  • Ochsner/MD Anderson Cancer Center

    RECRUITING

    New Orleans, Louisiana, 70121, United States

  • Precision NextGen Oncology

    RECRUITING

    Beverly Hills, California, 90212, United States

  • Renovatio Clinical

    TERMINATED

    El Paso, Texas, 79915, United States

  • Renovatio Clinical

    TERMINATED

    The Woodlands, Texas, 77380, United States

  • Sarah Cannon Research Institute

    RECRUITING

    Nasville, Tennessee, 37203, United States

  • UPMC Hillman Cancer Center

    TERMINATED

    Pittsburgh, Pennsylvania, 15232, United States

  • XCancer Research Network/Dothan Hematology & Oncology

    RECRUITING

    Dothan, Alabama, 36303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.